$AVGR
Avinger Inc Stock $avgr

$avgr Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000143774919004223 Filed on March 06, 2019

Income Statement

Concept	2019 Q1	2017 Q4	2017
Revenue	$1.840M	$1.910M	$9.934M
YoY Change	1.71%	-59.19%	-48.29%
Cost Of Revenue	$1.467M	$1.730M	$13.00M
YoY Change	3.67%	-53.24%	-10.02%
Gross Profit	$373.0K	$180.0K	-$3.068M
YoY Change	-5.33%	-81.63%	-164.32%
Gross Profit Margin	20.27%	9.42%	-30.88%
Selling, General & Admin	$3.986M	$4.690M	$25.12M
YoY Change	-11.42%	-47.36%	-37.12%
% of Gross Profit	1068.63%	2605.56%
Research & Development	$1.414M	$1.980M	$11.32M
YoY Change	-20.43%	-50.87%	-27.16%
% of Gross Profit	379.09%	1100.0%
Depreciation & Amortization	$200.0K	$320.0K	$1.476M
YoY Change	-27.8%	-21.95%	-2.25%
% of Gross Profit	53.62%	177.78%
Operating Expenses	$5.400M	$6.670M	$39.48M
YoY Change	-13.97%	-48.45%	-28.83%
Operating Profit	-$5.027M	-$6.490M	-$42.55M
YoY Change	-14.55%	-45.74%	-16.09%
Interest Expense	$350.0K	-$1.560M	$6.299M
YoY Change	-92.51%	1.96%	-216.43%
% of Operating Profit
Other Income/Expense, Net	$240.0K		$11.00K
YoY Change	-0.41%
Pretax Income	-$5.060M	-$10.15M	-$48.73M
YoY Change	-50.78%	-24.81%	-13.18%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$5.055M	-$10.15M	-$48.73M
YoY Change	-50.83%	-24.81%	-13.18%
Net Earnings / Revenue	-274.73%	-531.41%	-490.56%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.191M	-$126.9M	-$696.1M
COMMON SHARES
Basic Shares Outstanding	42.30M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2017 Q4	2017
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.71M	$5.390M	$5.390M
YoY Change	15.88%	-85.07%	-85.07%
Cash & Equivalents	$16.71M	$5.389M	$5.390M
Short-Term Investments
Other Short-Term Assets	$2.340M	$640.0K	$640.0K
YoY Change	101.72%	-3.03%	-3.03%
Inventory	$3.955M	$4.295M	$4.300M
Prepaid Expenses
Receivables	$1.112M	$1.127M	$1.130M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$24.11M	$11.45M	$11.45M
YoY Change	15.15%	-76.53%	-76.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.140M	$2.950M	$2.950M
YoY Change	-11.93%	-35.31%	-35.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$687.0K	$690.0K
YoY Change		227.14%	228.57%
Total Long-Term Assets	$2.140M	$3.637M	$3.640M
YoY Change	-29.14%	-23.75%	-23.69%
TOTAL ASSETS
Total Short-Term Assets	$24.11M	$11.45M	$11.45M
Total Long-Term Assets	$2.140M	$3.637M	$3.640M
Total Assets	$26.25M	$15.09M	$15.09M
YoY Change	9.57%	-71.83%	-71.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$969.0K	$1.273M	$1.270M
YoY Change	-55.14%	-20.93%	-21.12%
Accrued Expenses	$906.0K	$3.597M	$4.410M
YoY Change	-51.29%	-38.72%	-24.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.840M	$44.74M	$44.74M
YoY Change	4.26%	8.36%	8.36%
Total Short-Term Liabilities	$12.94M	$50.48M	$50.48M
YoY Change	8.25%	3.5%	3.51%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$38.00K	$301.0K	$300.0K
YoY Change	-65.45%	-45.27%	-45.45%
Total Long-Term Liabilities	$38.00K	$301.0K	$300.0K
YoY Change	-65.45%	-45.27%	-45.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.94M	$50.48M	$50.48M
Total Long-Term Liabilities	$38.00K	$301.0K	$300.0K
Total Liabilities	$12.97M	$50.78M	$50.78M
YoY Change	7.58%	2.96%	2.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$333.9M	-$301.3M
YoY Change
Common Stock	$347.2M	$265.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.28M	-$35.69M	-$35.69M
YoY Change
Total Liabilities & Shareholders Equity	$26.25M	$15.09M	$15.09M
YoY Change	9.57%	-71.83%	-71.83%

Cashflow Statement

Concept	2019 Q1	2017 Q4	2017
OPERATING ACTIVITIES
Net Income	-$5.055M	-$10.15M	-$48.73M
YoY Change	-50.83%	-24.81%	-13.18%
Depreciation, Depletion And Amortization	$200.0K	$320.0K	$1.476M
YoY Change	-27.8%	-21.95%	-2.25%
Cash From Operating Activities	-$5.996M	-$5.180M	-$34.48M
YoY Change	-12.81%	-52.04%	-35.04%
INVESTING ACTIVITIES
Capital Expenditures	$83.00K	$0.00	$45.00K
YoY Change		-100.0%	-104.64%
Acquisitions
YoY Change
Other Investing Activities	$20.00K	$0.00	$0.00
YoY Change	-60.0%
Cash From Investing Activities	-$65.00K	$0.00	-$41.00K
YoY Change	-241.3%	-100.0%	-95.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$246.0K
YoY Change			-99.34%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.358M	400.0K	3.810M
YoY Change	-59.91%	-89.25%	-91.91%
NET CHANGE
Cash From Operating Activities	-5.996M	-5.180M	-34.48M
Cash From Investing Activities	-65.00K	0.000	-41.00K
Cash From Financing Activities	6.358M	400.0K	3.810M
Net Change In Cash	297.0K	-4.780M	-30.71M
YoY Change	-96.71%	-33.43%	341.19%
FREE CASH FLOW
Cash From Operating Activities	-$5.996M	-$5.180M	-$34.48M
Capital Expenditures	$83.00K	$0.00	$45.00K
Free Cash Flow	-$6.079M	-$5.180M	-$34.52M
YoY Change	-11.6%	-51.59%	-33.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2017	avgr	Increase Decrease In Other Long Term Liabilities And Accrued Interest IncreaseDecreaseInOtherLongTermLiabilitiesAndAccruedInterest	-259000
CY2018	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	5634000
CY2017	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	3252000
CY2018	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature	5216000
CY2017	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature
CY2018	avgr	Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts	15525000
CY2017	avgr	Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts
CY2018Q4	avgr	Proceeds From Issuance Or Sale Of Equity Net ProceedsFromIssuanceOrSaleOfEquityNet	10200000
CY2018Q1	avgr	Proceeds From Issuance Or Sale Of Equity Net ProceedsFromIssuanceOrSaleOfEquityNet	15500000
CY2018	avgr	Increase Decrease In Other Long Term Liabilities And Accrued Interest IncreaseDecreaseInOtherLongTermLiabilitiesAndAccruedInterest	-260000
CY2018	avgr	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate Amount EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRateAmount
CY2017	avgr	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate Amount EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRateAmount	35953000
CY2018	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	2918000
CY2017	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends
CY2018Q4	avgr	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	111000
CY2017Q4	avgr	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	57000
CY2018Q4	avgr	Accrued Restructuring Charges Current AccruedRestructuringChargesCurrent	98000
CY2017Q4	avgr	Accrued Restructuring Charges Current AccruedRestructuringChargesCurrent	98000
CY2018Q4	avgr	Accrued Travel Expenses Current AccruedTravelExpensesCurrent	74000
CY2017Q4	avgr	Accrued Travel Expenses Current AccruedTravelExpensesCurrent	90000
CY2016Q1	avgr	Common Stock Offering Maximum Aggregate Value CommonStockOfferingMaximumAggregateValue	150000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Cash And Certain Cash Equivalents Minimum DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum	5000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Cash And Certain Cash Equivalents Minimum DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum	50000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Cash And Certain Cash Equivalents Minimum DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum	2500000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Cash And Certain Cash Equivalents Minimum DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum	3500000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Prepayment Multiplier For Revenue Shortfall DebtInstrumentCovenantCompliancePrepaymentMultiplierForRevenueShortfall	2
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue After Year Five DebtInstrumentCovenantComplianceTargetMinimumRevenueAfterYearFive	70000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Eighth Year DebtInstrumentCovenantComplianceTargetMinimumRevenueEighthYear	25000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Fifth Year DebtInstrumentCovenantComplianceTargetMinimumRevenueFifthYear	60000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue First Year DebtInstrumentCovenantComplianceTargetMinimumRevenueFirstYear	7000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Fourth Year DebtInstrumentCovenantComplianceTargetMinimumRevenueFourthYear	50000000
CY2016Q4	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Second Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSecondYear	18000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Second Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSecondYear	23000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Seventh Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSeventhYear	20000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Sixth Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSixthYear	15000000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Third Year DebtInstrumentCovenantComplianceTargetMinimumRevenueThirdYear	40000000
CY2015Q3	avgr	Debt Instrument Final Facility Fee Percentage DebtInstrumentFinalFacilityFeePercentage	0.07
CY2018Q1	avgr	Debt Instrument Final Facility Fee Percentage DebtInstrumentFinalFacilityFeePercentage	0.15
CY2015Q3	avgr	Debt Instrument Financing Fee Percentage DebtInstrumentFinancingFeePercentage	0.015
CY2015Q3	avgr	Debt Instrument Redemption Annual Decline In Prepayment Premium Percentage DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage	0.01
CY2015Q3	avgr	Debt Instrument Redemption Initial Prepayment Premium Percentage DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage	0.05
CY2015Q3	avgr	Debt Instrument Redemption Prepayment Premium Percentage After Fifth Year DebtInstrumentRedemptionPrepaymentPremiumPercentageAfterFifthYear	0
CY2018	avgr	Disposal Of Fully Depreciated Property And Equipment DisposalOfFullyDepreciatedPropertyAndEquipment	2849000
CY2017	avgr	Disposal Of Fully Depreciated Property And Equipment DisposalOfFullyDepreciatedPropertyAndEquipment	1738000
CY2018	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2018	dei	Entity Registrant Name EntityRegistrantName	Avinger Inc
CY2018	dei	Trading Symbol TradingSymbol	avgr
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001506928
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018Q3	avgr	Proceeds From Issuance Or Sale Of Equity Net ProceedsFromIssuanceOrSaleOfEquityNet	3000000
CY2018	avgr	Proceeds From Public Offerings Net Of Issuance Costs ProceedsFromPublicOfferingsNetOfIssuanceCosts	3026000
CY2017	avgr	Proceeds From Public Offerings Net Of Issuance Costs ProceedsFromPublicOfferingsNetOfIssuanceCosts	3589000
CY2018	avgr	Proceeds From The Issuance Of Common Stock And Convertible Preferred Stock Net Of Issuance Costs ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts	10179000
CY2017	avgr	Proceeds From The Issuance Of Common Stock And Convertible Preferred Stock Net Of Issuance Costs ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts
CY2018	avgr	Proceeds From The Issuance Of Common Stock Under Officers And Directors Purchase Plan ProceedsFromTheIssuanceOfCommonStockUnderOfficersAndDirectorsPurchasePlan	21000
CY2017	avgr	Proceeds From The Issuance Of Common Stock Under Officers And Directors Purchase Plan ProceedsFromTheIssuanceOfCommonStockUnderOfficersAndDirectorsPurchasePlan
CY2018	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	451000
CY2017	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	425000
CY2018	avgr	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
CY2018	avgr	Stock Issued During Period Value Purchase Agreement StockIssuedDuringPeriodValuePurchaseAgreement	314000
CY2018	avgr	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	581000
CY2018	avgr	Transfer Between Inventories And Property And Equipment TransferBetweenInventoriesAndPropertyAndEquipment	51000
CY2017	avgr	Transfer Between Inventories And Property And Equipment TransferBetweenInventoriesAndPropertyAndEquipment	153000
CY2018	avgr	Warranty Period WarrantyPeriod	P1Y
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Type DocumentType	10-K
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42297117
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019Q1	dei	Entity Public Float EntityPublicFloat	28800000
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1148000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1273000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1154000
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1127000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1449000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3597000
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	41000
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	288000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3155000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5564000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	338311000
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	265636000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	2918000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4966000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3080000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3080000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4966000
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	260000
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	146000
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21814364
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	135448
CY2018Q4	us-gaap	Assets Assets	23699000
CY2017	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	218000
CY2017Q4	us-gaap	Assets Assets	15088000
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	117000
CY2017	us-gaap	Cost Of Revenue CostOfRevenue	13002000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16410000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	21621000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	11451000
CY2018Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5389000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36096000
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	11021000
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-30707000
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	47575393
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	53803
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34921999
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	833597
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34921999
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	833597
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	34000
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	6531000
CY2018	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	42794000
CY2017	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1
CY2018Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
CY2017Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	464000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	78082000
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	70501000
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	70286000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	62057000
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	604000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3655000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3632000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4317000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4208000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	78082000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70501000
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	176000
CY2018	us-gaap	Depreciation Depreciation	934000
CY2017	us-gaap	Depreciation Depreciation	1476000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1281000
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1476000
CY2018Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	2918000
CY2017Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.34
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-74.74
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1197000
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	863000
CY2018	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2017	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-13000
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	11000
CY2018	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	7000
CY2017	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-18000
CY2018	us-gaap	Gross Profit GrossProfit	1384000
CY2017	us-gaap	Gross Profit GrossProfit	-3068000
CY2018	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6582000
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-22554000
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5787000
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-16565000
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	228000
CY2017	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims
CY2018Q4	us-gaap	Liabilities Liabilities	14239000
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3009000
CY2018Q4	us-gaap	Inventory Net InventoryNet	3422000
CY2017Q4	us-gaap	Inventory Net InventoryNet	4295000
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	525000
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1877000
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1023000
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	993000
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch
CY2017	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	229000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-125000
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-334000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	160000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2318000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2208000
CY2017	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1205000
CY2018	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	334000
CY2017	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1945000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	92000
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1181000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-340000
CY2017	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	475000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-22000
CY2018	us-gaap	Interest Expense InterestExpense	5692000
CY2017	us-gaap	Interest Expense InterestExpense	6299000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	60000
CY2017	us-gaap	Interest Paid Net InterestPaidNet	3942000
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	364000
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2102000
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1162000
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1286000
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	158000
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	914000
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	5500000
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	214000
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	108000
CY2018	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	106000
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	301000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11000
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1833000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	418000
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	550000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	687000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	41000
CY2017Q4	us-gaap	Liabilities Liabilities	50778000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23699000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15088000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14198000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	50477000
CY2015Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	50000000
CY2018Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent
CY2017Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1760000
CY2018	us-gaap	Litigation Settlement Expense LitigationSettlementExpense
CY2017	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	1760000
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> Organization</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Organization, Nature of Business</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2007.</div> The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “OCT”) </div>visualization with interventional catheters and is the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company’s Lumivascular platform consists of a capital component, Lightbox, as well as a variety of disposable catheter products. The Company’s current products include its non-imaging catheters, Wildcat and Kittycat, as well as its Lumivascular platform products, Ocelot, Ocelot PIXL and Ocelot MVRX, all of which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(k) clearance from the U.S. Food and Drug Administration (“FDA”) for commercialization of Pantheris, the Company’s image-guided atherectomy system, designed to allow physicians to precisely remove arterial plaque in PAD patients. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2018, </div>the Company also received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(K) clearance from the FDA for its next-generation of Pantheris. The Company submitted a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(k) filing in respect of Pantheris SV, a lower profile Pantheris, in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2018 </div>and received CE Marking approval for Pantheris SV in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 2018. </div>The Company has sales in the U.S. and select international markets. The Company is located in Redwood City, California.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Liquidity Matters</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> Presentation of Financial Statements - Going Concern (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">205</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div>) requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entity’s ability to continue as a going concern within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year from the date of the issuance of these financial statements. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company had an accumulated deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$328.9</div> million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16.4</div> million at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and expected revenues and funds from operations will be sufficient to allow the Company to fund its current operations through at least the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div> Even though we received net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.2</div> million from the sale of our Series C Preferred Stock and common stock in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2018 </div>offering, net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.5</div> million from the sale of our Series B preferred stock and warrants in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018 </div>offering, and net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million from the sale of common stock and warrants in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2018 </div>offering, the Company will need to raise additional funds through future equity or debt financings within the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months to meet its operational needs and capital requirements for product development, clinical trials and commercialization and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>subsequently require additional fundraising. The Company can provide <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> create substantial dilution for our existing stockholders. Given the recent decline in the Company’s stock price, any financing that we undertake in the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months could cause substantial dilution to our existing stockholders, there can be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>have to significantly reduce its operations or delay, scale back or discontinue the development of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more of its products. The financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding. Additionally, due to the substantial doubt about the Company’s ability to continue operating as a going concern and the material adverse change clause in the Loan Agreement with CRG, the entire amount of borrowings at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> has been classified as current in these financial statements. CRG has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> invoked the material adverse change clause.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Public Offerings</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company filed a universal shelf registration statement to offer up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$150,000,000</div> of its securities and entered into an “at-the-market” program pursuant to a Sales Agreement with Cowen and Company (“Cowen”), through which it <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may, </div>from time to time, issue and sell shares of common stock having an aggregate offering value of up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$50,000,000.</div> The shelf registration statement also covers the resale of the shares sold to CRG in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015.</div> The registration statement was declared effective by the SEC on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> During the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company sold <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">189,684</div> shares of common stock through the “at-the-market” program at an average price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$17.68</div> per common share and raised net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,187,000,</div> after payment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$101,000</div> in commissions and fees to Cowen. During the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company sold <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,374</div> shares, respectively, of common stock through the “at-the-market” program at an average price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$194.74</div> per common share and raised net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,171,000,</div> after payment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$160,000</div> in commissions and fees to Cowen. Due to the SEC’s “baby shelf rules,” which prohibit companies with a public float of less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$75</div> million from issuing securities under a shelf registration statement in excess of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> of such company’s public float in a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div>-month period, the Company is unable to issue more shares in its “at-the-market” program at this time.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> we completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,979</div> shares of Series B preferred stock and warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,979,000</div> shares of common stock. As a result, we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.5</div> million after underwriting discounts, commissions, legal and accounting fees. Each share of Series B preferred stock is accompanied by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> warrant that expires on the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seventh</div> anniversary of the date of issuance to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500</div> shares of common stock (the “Series <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> warrants”) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> warrant that expires on the earlier of (i) the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seventh</div> anniversary of the date of issuance or (ii) the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60th</div> calendar day following the receipt and announcement of FDA clearance of our Pantheris below-the-knee device (or the same or similar product with a different name) to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500</div> shares of common stock; provided, however, if at any time during such <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div>-day period the volume weighted average price for any trading day is less than the then effective exercise price, the termination date shall be extended to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div> year anniversary of the initial exercise date (the “Series <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> warrants”). In addition, pursuant to the Series A Purchase Agreement, we issued to CRG <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,800</div> shares of Series A preferred stock at the closing of the Series B Offering. The Series A preferred stock was issued in exchange for the conversion of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$38.0</div> million of the outstanding principal amount of their senior secured term loan (plus the back-end fee and prepayment premium applicable thereto), totaling approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$41.8</div> million. The Series A preferred stock is initially convertible into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,900,000</div> shares of common stock subject to certain limitations contained in the Series A Purchase Agreement.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> we entered into a securities purchase agreement with certain investors pursuant to which we agreed to sell and issue, in a registered direct offering, an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,166,180</div> shares of our common stock at an offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.6425</div> per share. In a concurrent private placement, or the Private Placement, we agreed to issue to these investors warrants exercisable for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of our common stock for each <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> shares purchased in the registered direct offering, which equals an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,083,091</div> shares of common stock. The closing of such registered direct offering and the concurrent Private Placement occurred on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> in connection with which we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million after deducting placement agent fees and other expenses payable by us and the conversion price of the outstanding shares of Series B preferred stock, issued in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018 </div>offering, was reduced to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.58</div> per share as a result. The warrants have an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.58</div> per share of our common stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be exercised from time to time beginning on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> and expire on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2021.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 1, 2018, </div>we completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,285,000</div><div style="display: inline; text-decoration: underline;"> </div>shares of common stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,586</div> shares of Series C convertible preferred stock (the “Series C preferred stock”). As a result, we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.2</div> million after underwriting discounts, commissions, legal and accounting fees. Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series C preferred stock will be entitled to receive distributions out of our assets, whether capital or surplus, of an amount equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share of Series C preferred stock before any distributions shall be made on the common stock but after distributions shall be made on any outstanding Series A preferred stock and any of our existing or future indebtedness. The Series C preferred stock has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> voting rights.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </div></div>
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29491000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3810000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-41000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18466000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34476000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-27558000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-48732000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35692000
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-48732000
CY2018	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	0
CY2018	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2018	us-gaap	Operating Expenses OperatingExpenses	23451000
CY2017	us-gaap	Operating Expenses OperatingExpenses	39484000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-22067000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-42552000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	899000
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1015000
CY2018	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	155000
CY2017	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45000
CY2018	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2918000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	25506000
CY2017	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact
CY2018Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	44718000
CY2017Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	0
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	45671
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	45671
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	635000
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	640000
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	314000
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	246000
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	28000
CY2017	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4000
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	581000
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises
CY2017Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	390000
CY2016Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	509000
CY2018Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	272000
CY2018Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	272000
CY2017Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	390000
CY2018	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	333000
CY2017	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	306000
CY2018	us-gaap	Profit Loss ProfitLoss	-27558000
CY2017	us-gaap	Profit Loss ProfitLoss	-48732000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5227000
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8468000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2078000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2950000
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	133000
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	125000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2594000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	291.73
CY2018	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations
CY2017	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	25000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6009000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11319000
CY2018	us-gaap	Restructuring Charges RestructuringCharges
CY2017	us-gaap	Restructuring Charges RestructuringCharges	1285000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-328885000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-301327000
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7915000
CY2017	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9934000
CY2018Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	435000
CY2017Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	31000000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	43305000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	246.97
CY2018Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	7486000
CY2017Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	44744000
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17442000
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25120000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	3080000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	4966000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	76645000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	79545000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	170.73
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	79545000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	170.73
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	272.58
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	349.37
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.67
CY2018Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	43305
CY2018Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	79545
CY2018Q4	us-gaap	Share Price SharePrice	0.30
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y149D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y251D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y251D
CY2018Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	246.97
CY2018Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	247.03
CY2018	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y251D
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	21000
CY2018	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	106000
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3589000
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	246000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	4241000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-35690000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	9460000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1747000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1536000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1760000
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	16000
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2017Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2018	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2017	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	29000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	211000
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuation of the common stock warrants, the valuation of compound embedded derivatives, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>undertake in the future, actual results <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>ultimately materially differ from these estimates and assumptions.</div></div></div></div></div></div></div></div></div></div></div>
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7600000
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-20900000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10687000
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	652000
CY2018	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0

Files In Submission

Name	View Source	Status
0001437749-19-004223-index-headers.html	Edgar Link	pending
0001437749-19-004223-index.html	Edgar Link	pending
0001437749-19-004223.txt	Edgar Link	pending
0001437749-19-004223-xbrl.zip	Edgar Link	pending
avgr-20181231.xml	Edgar Link	completed
avgr-20181231.xsd	Edgar Link	pending
avgr-20181231_cal.xml	Edgar Link	unprocessable
avgr-20181231_def.xml	Edgar Link	unprocessable
avgr-20181231_lab.xml	Edgar Link	unprocessable
avgr-20181231_pre.xml	Edgar Link	unprocessable
avgr20181231_10k.htm	Edgar Link	pending
ex_135993.htm	Edgar Link	pending
ex_135994.htm	Edgar Link	pending
ex_135995.htm	Edgar Link	pending
ex_136245.htm	Edgar Link	pending
ex_136785.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVGR
Avinger Inc Stock $avgr

2019 Q1 Form 10-K Financial Statement

#000143774919004223 Filed on March 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR Avinger Inc Stock $avgr

2019 Q1 Form 10-K Financial Statement

#000143774919004223 Filed on March 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR
Avinger Inc Stock $avgr